MenoZen VR for managing menopause symptoms
Official title: MenoZen VR for Menopause Symptom Management: Phase 2
Run by Mayo Clinic · NCT07633743 · Data updated 2026-11-12
This study tests whether MenoZen VR can help reduce hot flashes and other menopause symptoms in women aged 45–60 who have frequent hot flashes and can use a computer or smartphone at home.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 45 Years to 60 Years |
| Sex | Women only |
| Enrollment | 40 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Jacksonville, Florida) |
| Status | Recruiting |
| Started | September 28, 2026 |
| Main results expected | July 31, 2027 |
| Study ends | July 31, 2028 |
| Registry record updated | September 24, 2026 |
| Trial ID | NCT07633743 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are English-speaking women 45–60 years old with 28+ weekly hot flashes who can participate in 8 weeks of weekly VR sessions and have home internet access.
✕Probably not a fit
Individuals whose symptoms do not respond to the VR intervention or who cannot adhere to weekly sessions may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study examines the feasibility, acceptability, tolerability, and potential efficacy of MenoZen VR for managing menopause symptoms. Eligible participants are English-speaking women aged 45–60 with at least 28 hot flashes per week who can participate in weekly VR sessions for eight weeks. Participants must have access to a computer or smartphone and home Wi‑Fi and must not be on systemic hormone therapy or certain non-hormonal hot flash medications. The Mayo Clinic will sponsor the study with sessions conducted at Mayo Clinic in Jacksonville, Florida. The trial will assess how well participants can use the VR intervention and any changes in symptom burden over time.
Why it matters
Potential benefit: If successful, participants may experience a reduction in hot flashes and related menopause symptoms through VR-based therapy.
How similar studies have gone: Prior research suggests VR-based interventions can be acceptable and feasible for symptom management, but efficacy for menopause symptoms is still being explored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women currently between 45-60 years of age; * Have moderate to severe VMS, defined as 28 or more hot flashes per week (including night sweats) and were sufficient severity to prompt them to seek therapeutic intervention; * Are English-speaking; * Able to participate fully in all aspects of the study; * Have understood and signed study informed consent; * Have access to a computer or smartphone and home Wi-Fi; * Willing to participate in weekly VR sessions for 8 weeks. Exclusion Criteria: * Women receiving systemic menopause hormonal therapy (progesterone, testosterone, estrogen). Low-dose topical vaginal estrogen is okay; * Women receiving non-hormonal therapy for the management of hot flashes (fezolinetant or elinzanetant, any SSRI/SNRI, oxybytunin, and/or gabapentin being prescribed for hot flashes, if for other reasons and still with hot flashes then okay); * Women receiving active cognitive behavioral therapy (CBT) for hot flashes. CBT for mood symptoms is okay; * Have a known, active, untreated clinically significant psychiatric condition (severe depression, psychosis, bipolar disorder, or severe depression); * Have severe visual, auditory, or vestibular impairments that may interfere with VR use; * Have a facial/head deformity that will prohibit the wearing of a VR head mounted displace (HMD); * Self-reported history of acute and/or severe motion sickness; * Have had a seizure in the past year; * Concurrently enrolled in another intervention trial for menopause symptoms; * Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.
Where it's running
-
Mayo Clinic
Jacksonville, Florida, United States Recruiting
Study contacts
- Principal investigator: Chrisandra L. Shufelt, MD, MS — Mayo Clinic
- Study coordinator: Lauren Uy
- Email: Uy.Lauren@mayo.edu
- Phone: 904-953-5337
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hop extract vs soy isoflavone for menopausal symptoms
This study tests whether a full-spectrum hop extract helps reduce menopausal mood symptoms better than soy isoflavones in peri- and postmenopausal women.
-
Resveratrol and Estrogen Receptors in Postmenopausal Women with CAD
This study tests whether taking resveratrol is safe and can change estrogen-related markers in postmenopausal women with coronary artery disease.
-
Ashoka Bark and Shatavari for Menopause
This 12-week study tests whether a daily Ashoka Bark and Shatavari supplement helps reduce menopausal symptoms in postmenopausal women compared with a placebo.
-
Lifestyle changes to ease menopausal symptoms, sleep problems, and anxiety
Researchers are testing whether a structured lifestyle education program helps perimenopausal and postmenopausal women see fewer menopausal symptoms, better sleep, and less anxiety compared to usual care.
-
Pain and period life: does menstrual cycle or menopause change pain during root canals?
This study will see if pain during a root canal varies with menstrual cycle phase or menopausal status in adult patients.
-
Sex hormones, menopause, and exercise in aging women
This study tests how hormonal status and resistance training affect age-related muscle and nerve function in postmenopausal women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.